Community › Results & Progress

Roche's new GLP-1, Enicepatide.

15 replies12 peopleJul 23, 2026☆ Follow
Summary

What do early trial results show for Roche's Enicepatide and how might it fit among existing GLP-1 drugs?

Phase 2 data at 48 weeks showed 22.5% average weight loss that had not plateaued, with 26% of participants losing 30% or more body weight and a 5.9% dropout rate at the top dose. Participants also saw high rates of prediabetes reversal. Commenters note mechanistic similarities to tirzepatide but a different bias profile, and they expect triple agonists to outperform it while hoping lower side effects could still give it a market niche.

What this discussion establishesWhere people disagree

Whether single or dual agonists without triple activity can remain competitive unless priced very low.

Still open

How side-effect rates will ultimately compare once full data appear and when the drug might reach broader availability.

Nothing here is advice.

15 replies · 12 people
SteadyTimber22archiveopening postJul 23

Roche's 48-week phase 2 data show solid weight-loss numbers along with lower dropout and better tolerability than today's GLP-1 medicines. The dual agonist, once called CT388-103 and now Enicepatide, produced 22.5% weight loss at 48 weeks without any plateau, 26.1% of people lost 30% or more, and 73% of those with prediabetes returned to normal blood glucose. At the 24 mg dose the dropout rate was only 5.9%, roughly half that of other drugs in the class.

LikeSame experienceReply
IronKettle95archiveJul 23
↳ replying to @SteadyTimber22 (opening post)

I enjoy Christopher's videos when he's alone. Very informational.

LikeSame experienceReply
CopperSignal27archiveJul 23

Very similar to tirzepatide in many respects except it is a biased agonist toward cAMP at both GLP-1 and GIP, while tirzepatide is biased only at GLP-1. Weight-loss numbers look comparable and the low dropout rate stands out. I could not locate the actual paper to check side-effect rates. Weight loss had not plateaued at 48 weeks, so longer treatment should produce even more loss. It is difficult to predict how any of the new non-triple GLP drugs will fare; retatrutide is simply more effective and other triple agonists in development will likely be too. This candidate might stand out through fewer side effects given the low dropout, which could help it in the market versus tirzepatide. I see no realistic path for injectable GLP-1-only drugs in development unless they are made cheap and launched quickly before many more options appear.

LikeSame experienceReply
ClearBeacon24archiveJul 23
↳ replying to @SteadyTimber22 (opening post)

So another tirzepitide?

LikeSame experienceReply
SlowLedger31archiveJul 23
↳ replying to @ClearBeacon24

Missing the classic version here but stocked with its cheaper copycat instead. 😂

LikeSame experienceReply
ClearBeacon24archiveJul 23
↳ replying to @SlowLedger31

Same, Walmart $1 2 liter

LikeSame experienceReply
GreyAlder39archiveJul 23

I noticed they're starting to look for participants in the third stage of the trial.

LikeSame experienceReply
GreyAlder39archiveJul 23

Another compound they're developing mimics amylin. Fresh findings from their work on weight management will be shared at a big diabetes gathering next year. New results from the second stage of trials stress how well it performs along with its safety profile, suggesting it could achieve top level fat reduction for many people dealing with the issue.

LikeSame experienceReply
SteadySignal69archiveJul 23

Seems we're only seeing the start of a big surge in new methods for medications aimed at shedding pounds. Before long the versions we end up using could turn out far more advanced than the ones around today.

LikeSame experienceReply
CopperBeacon24archiveJul 23
↳ replying to @SteadySignal69

It's obvious those two early choices have fallen way out of favor already.

LikeSame experienceReply
GreyAlder39archiveJul 23
↳ replying to @SteadySignal69

With multiple approaches now available for extending duration, I expect the first compounds will be close matches to current ones but tweaked just enough to skirt existing legal protections. There could also be attempts at versions aimed at changes in people who respond poorly, though making those will likely prove tough. On top of that, some patients may resist anything but the original versions, much like what occurred in heart medicine.

LikeSame experienceReply
LevelBeacon74archiveJul 23
↳ replying to @SlowLedger31

That beverage is what I consume and it amuses me.

LikeSame experienceReply
BrightBeacon35archiveJul 23

I'm really looking forward to agonists four and five showing up at some point. How much longer until they appear?

LikeSame experienceReply
SlowLedger31archiveJul 23
↳ replying to @BrightBeacon35

These days you might need to search around for the newest developments. To me the truly game changing material still depends on that biological situation at the firm. No reason to let go now if its worth could multiply ten times overnight Haha

LikeSame experienceReply
AmberCinder46archiveJul 23
↳ replying to @GreyAlder39

Before long I guess I'll have to hunt down a larger freezer 😞

LikeSame experienceReply
SlowThistle88archiveJul 25
↳ replying to @CopperSignal27

Actual rivals around here might reduce overall costs. I'll keep getting my supplies the usual way, though this shift could transform things for anyone avoiding unofficial channels.

LikeSame experienceReply

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.

Sign inCreate an account
Roche's new GLP-1, Enicepatide. · ZyraTrack Community